

(12) International Application Status Report

Received at International Bureau: 27 January 2018 (27.01.2018)

Information valid as of: 03 July 2018 (03.07.2018)

Report generated on: 05 March 2025 (05.03.2025)

(10) Publication number:

WO2019/120527

(43) Publication date:

27 June 2019 (27.06.2019)

(26) Publication language:

English (EN)

(21) Application Number:

PCT/EP2017/083944

(22) Filing Date:

20 December 2017 (20.12.2017)

(25) Filing language:

English (EN)

(51) International Patent Classification:

C07K 16/18 (2006.01); **G01N 33/569** (2006.01); **A61K 39/00** (2006.01)

(71) Applicant(s):

HENEKA, Michael [DE/DE]; Waldauweg 18 53127 Bonn (DE) (*for all designated states*)

(72) Inventor(s):

HENEKA, Michael; Waldauweg 18 53127 Bonn (DE)

LATZ, Eicke; Viktoriaplatz 2 53173 Bonn (DE)

VENEGAS MALDONADO, Carmen; Wenzelgasse 44 53111 Bonn (DE)

WALTER, Jochen; Am Steg 12 53757 Sankt Augustin (DE)

KUMAR, Sathish; Am Römerkastell 7 53111 Bonn (DE)

(74) Agent(s):

VON STOSCH, Andreas; Prinzregentenstr. 22 80538 München (DE)

(54) Title (EN): NOVEL MEANS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES

(54) Title (FR): NOUVEAUX MOYENS ET MÉTHODES PERMETTANT DE TRAITER DES MALADIES NEURODÉGÉNÉRATIVES

(57) Abstract:

(EN): The present invention provides novel means and methods for treating and diagnosing neurodegenerative diseases. In particular, said means and methods include ligands of the apoptosis-associated speck-like protein containing a CARD. Further provided herein are nucleic acids encoding such ligands, and vectors and host cells comprising the same. The present invention further relates to pharmaceutical compositions as well as kits and diagnostic kits.

(FR): La présente invention concerne de nouveaux moyens et des méthodes permettant de traiter et de diagnostiquer des maladies neurodégénératives. En particulier, lesdits moyens et méthodes comprennent des ligands de la protéine de type speck associée à l'apoptose contenant une CARD. L'invention concerne en outre des acides nucléiques codant pour de tels ligands, des vecteurs et des cellules hôtes les comprenant. La présente invention concerne en outre des compositions pharmaceutiques ainsi que des kits et des kits de diagnostic.

International search report:

Received at International Bureau: 19 June 2018 (19.06.2018) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM